Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Janet Schibler"'
Autor:
Xiaoxiao Liu, Naru Sato, Tomohiro Yabushita, Jingmei Li, Yuhan Jia, Moe Tamura, Shuhei Asada, Takeshi Fujino, Tsuyoshi Fukushima, Taishi Yonezawa, Yosuke Tanaka, Tomofusa Fukuyama, Akiho Tsuchiya, Shiori Shikata, Hiroyuki Iwamura, Chieko Kinouchi, Kensuke Komatsu, Satoshi Yamasaki, Tatsuhiro Shibata, Atsuo T Sasaki, Janet Schibler, Mark Wunderlich, Eric O'Brien, Benjamin Mizukawa, James C Mulloy, Yuki Sugiura, Hitoshi Takizawa, Takuma Shibata, Kensuke Miyake, Toshio Kitamura, Susumu Goyama
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 1, Pp n/a-n/a (2023)
Abstract Inosine monophosphate dehydrogenase (IMPDH) is a rate‐limiting enzyme in de novo guanine nucleotide synthesis pathway. Although IMPDH inhibitors are widely used as effective immunosuppressants, their antitumor effects have not been proven
Externí odkaz:
https://doaj.org/article/80b4174013704cb29ecfb11251a79951
Autor:
Xiaoxiao Liu, Naru Sato, Tomohiro Yabushita, Jingmei Li, Yuhan Jia, Moe Tamura, Shuhei Asada, Takeshi Fujino, Tsuyoshi Fukushima, Taishi Yonezawa, Yosuke Tanaka, Tomofusa Fukuyama, Akiho Tsuchiya, Shiori Shikata, Hiroyuki Iwamura, Chieko Kinouchi, Kensuke Komatsu, Satoshi Yamasaki, Tatsuhiro Shibata, Atsuo T Sasaki, Janet Schibler, Mark Wunderlich, Eric O'Brien, Benjamin Mizukawa, James C Mulloy, Yuki Sugiura, Hitoshi Takizawa, Takuma Shibata, Kensuke Miyake, Toshio Kitamura, Susumu Goyama
Publikováno v:
EMBO molecular medicineReferences.
Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme in de novo guanine nucleotide synthesis pathway. Although IMPDH inhibitors are widely used as effective immunosuppressants, their antitumor effects have not been proven in the clin
Publikováno v:
Experimental hematology. 72
Transcription factor RUNX1 plays a crucial role in hematopoiesis and its activity is tightly regulated at both the transcriptional and posttranslational levels. However, translational control of RUNX1 expression has not been fully understood. In this
Autor:
Whitney Miller, Tadaichi Kitamura, Leah Rosenfeldt, James C. Mulloy, Benjamin Mizukawa, Mahesh Shrestha, Joseph S. Palumbo, Susumu Goyama, Eric O'Brien, Janet Schibler
Eradication of leukemia stem cells (LSCs) is the ultimate goal of treating acute myeloid leukemia (AML). We recently showed that the combined loss of Runx1/Cbfb inhibited the development of MLL-AF9-induced AML. However, c-Kit+/Gr-1− cells remained
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f48e4b526a5f0849f8502a6ff3bbb448
https://europepmc.org/articles/PMC5418093/
https://europepmc.org/articles/PMC5418093/
Autor:
Susan P. Whitman, Shan Lin, Mahesh Shrestha, Janet Schibler, Kevin A. Link, Nicolas Nassar, Anjelika Gasilina, Constanze Bonifer, Anetta Ptasinska, Deedra Nicolet, Olaf Heidenreich, Clara D. Bloomfield, Jianjun Chen, Susumu Goyama, Salam A. Assi, Toshio Kitamura, James C. Mulloy
Publikováno v:
Leukemia. 30(3)
The t(8;21) rearrangement, which creates the AML1-ETO fusion protein, represents the most common chromosomal translocation in acute myeloid leukemia (AML). Clinical data suggest that CBL mutations are a frequent event in t(8;21) AML, but the role of
Autor:
Toshio Kitamura, Yuto Izawa, Y Hayashi, Motoki Saito, Kazutaka Sumita, Hiroyuki Iwamura, Janet Schibler, Susumu Goyama, James C. Mulloy, Atsuo T. Sasaki, Satoshi Kofuji, Shiori Shikata
Publikováno v:
Blood. 128:750-750
Uncontrolled cell proliferation is a hallmark of cancer and requires adequate nucleotide biosynthesis. Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme that catalyzes the conversion of IMP to XMP at the branch point of guanine nu
Autor:
James C. Mulloy, Eric O'Brien, Whitney Miller, Toshio Kitamura, Joseph S. Palumbo, Mahesh Shrestha, Leah Rosenfeldt, Benjamin Mizukawa, Susumu Goyama, Janet Schibler
Publikováno v:
Blood. 128:2730-2730
Leukemic stem cells (LSCs) are capable of limitless self-renewal and indefinitely propagating leukemia. Eradication of LSCs is the ultimate goal of treating acute myeloid leukemia (AML). Using a mouse model of AML induced by the MLL-fusion protein ML
Autor:
Benjamin Mizukawa, Kevin A. Link, Mineo Kurokawa, H. Leighton Grimes, Susumu Goyama, Nahoko Nishimoto, Gang Huang, Yalan Rao, Masahiro Nakagawa, Mark Wunderlich, Yue Zhang, Janet Schibler, Pengfei Liu, James C. Mulloy, Andre Olsson, Lea Cunningham
Publikováno v:
The Journal of clinical investigation. 123(9)
RUNX1 is generally considered a tumor suppressor in myeloid neoplasms. Inactivating RUNX1 mutations have frequently been found in patients with myelodysplastic syndrome (MDS) and cytogenetically normal acute myeloid leukemia (AML). However, no somati
Autor:
Kevin A. Link, James C. Mulloy, Shan Lin, Mahesh Shrestha, Nicolas Nassar, Anjelika Gasilina, Susumu Goyama, Janet Schibler
Publikováno v:
Experimental Hematology. 42:S36
CBLis amultifunctional protein engaged in the regulation of intracellular signaling pathways. Recent studies have found CBL mutations and deletions in a variety of myeloid diseases. In acute myeloid leukemia (AML), CBL mutations are associated with c
Autor:
James C. Mulloy, Yalan Rao, Gang Huang, Mark Wunderlich, Kevin A. Link, Susumu Goyama, Janet Schibler
Publikováno v:
Blood. 118:870-870
Abstract 870 RUNX1 is generally considered a tumor suppressor in myeloid neoplasms. Blocking RUNX1 function has been implicated in development of core-binding factor (CBF) leukemia and MLL-rearranged leukemia. In addition, inactivating RUNX1 mutation